Damoctocog alfa pegol

Drug Profile

Damoctocog alfa pegol

Alternative Names: BAY-949027; Damoctocog alfa pegol; peg rFVIII; PEG rFVIII mutein; PEGylated B-Domain-Delted Recombinant rFVIII; PEGylated BDD-rFVIII; rFVIII glycopegylated

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemophilia A
  • Phase II Haemorrhage

Most Recent Events

  • 23 Nov 2016 Bayer plans an observational clinical trial for Haemophilia A in USA, France, Austria, Israel and Netherlands (IV, Infusion) (NCT02971930)
  • 15 Mar 2016 Biomarkers information updated
  • 07 Oct 2015 Bayer re-initiates enrolment in the phase III PROTECT VIII Kids trial for Haemophilia A in USA, European Union, Argentina, Canada and Israel (NCT01775618; EudraCT2012-004434-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top